Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium.

Minlikeeva AN, Cannioto R, Jensen A, Kjaer SK, Jordan SJ, Diergaarde B, Szender JB, Odunsi K, Almohanna H, Mayor P, Starbuck K, Zsiros E, Bandera EV, Cramer DW, Doherty JA, DeFazio A; Australian Ovarian Cancer Study Group, Edwards R, Goode EL, Goodman MT, Høgdall E, Matsuo K, Mizuno M, Nagle CM, Ness RB, Paddock LE, Pearce CL, Risch HA, Rossing MA, Terry KL, Wu AH, Modugno F, Webb PM, Moysich KB; Ovarian Cancer Association Consortium.

Cancer Causes Control. 2019 May;30(5):537-547. doi: 10.1007/s10552-019-01157-3. Epub 2019 Mar 23.

2.

Ultrarestrictive Opioid Prescription Protocol for Pain Management After Gynecologic and Abdominal Surgery.

Mark J, Argentieri DM, Gutierrez CA, Morrell K, Eng K, Hutson AD, Mayor P, Szender JB, Starbuck K, Lynam S, Blum B, Akers S, Lele S, Paragh G, Odunsi K, de Leon-Casasola O, Frederick PJ, Zsiros E.

JAMA Netw Open. 2018 Dec 7;1(8):e185452. doi: 10.1001/jamanetworkopen.2018.5452.

3.

Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer.

Starbuck KD, Szender JB, Duncan WD, Morrell K, Etter JL, Zsiros E, Odunsi K, Moysich K, Eng KH.

PLoS One. 2018 Nov 12;13(11):e0206913. doi: 10.1371/journal.pone.0206913. eCollection 2018.

4.

Hereditary association between testicular cancer and familial ovarian cancer: A Familial Ovarian Cancer Registry study.

Etter JL, Eng K, Cannioto R, Kaur J, Almohanna H, Alqassim E, Szender JB, Joseph JM, Lele S, Odunsi K, Moysich KB.

Cancer Epidemiol. 2018 Apr;53:184-186. doi: 10.1016/j.canep.2018.02.005. Epub 2018 Feb 27.

5.

Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study.

Eng KH, Szender JB, Etter JL, Kaur J, Poblete S, Huang RY, Zhu Q, Grzesik KA, Battaglia S, Cannioto R, Krolewski JJ, Zsiros E, Frederick PJ, Lele SB, Moysich KB, Odunsi KO.

PLoS Genet. 2018 Feb 15;14(2):e1007194. doi: 10.1371/journal.pgen.1007194. eCollection 2018 Feb.

6.

Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer.

Szender JB, Kaur J, Clayback K, Hutton ML, Mikkelson J, Odunsi K, Dresbold C.

Int J Gynecol Cancer. 2018 Jan;28(1):26-33. doi: 10.1097/IGC.0000000000001122.

7.

History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium.

Minlikeeva AN, Freudenheim JL, Eng KH, Cannioto RA, Friel G, Szender JB, Segal B, Odunsi K, Mayor P, Diergaarde B, Zsiros E, Kelemen LE, Köbel M, Steed H, deFazio A, Jordan SJ, Fasching PA, Beckmann MW, Risch HA, Rossing MA, Doherty JA, Chang-Claude J, Goodman MT, Dörk T, Edwards R, Modugno F, Ness RB, Matsuo K, Mizuno M, Karlan BY, Goode EL, Kjær SK, Høgdall E, Schildkraut JM, Terry KL, Cramer DW, Bandera EV, Paddock LE, Kiemeney LA, Massuger LFAG, Sutphen R, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Pearce CL, Wu AH, Kupryjanczyk J, Jensen A, Webb PM, Moysich KB; Ovarian Cancer Association Consortium; Australian Ovarian Cancer Study Group.

Cancer Epidemiol Biomarkers Prev. 2017 Sep;26(9):1470-1473. doi: 10.1158/1055-9965.EPI-17-0367.

8.

History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report.

Minlikeeva AN, Freudenheim JL, Cannioto RA, Eng KH, Szender JB, Mayor P, Etter JL, Cramer DW, Diergaarde B, Doherty JA, Dörk T, Edwards R, deFazio A, Friel G, Goodman MT, Hillemanns P, Høgdall E, Jensen A, Jordan SJ, Karlan BY, Kjær SK, Klapdor R, Matsuo K, Mizuno M, Nagle CM, Odunsi K, Paddock L, Rossing MA, Schildkraut JM, Schmalfeldt B, Segal BH, Starbuck K, Terry KL, Webb PM, Zsiros E, Ness RB, Modugno F, Bandera EV, Chang-Claude J, Moysich KB.

Br J Cancer. 2017 Sep 26;117(7):1063-1069. doi: 10.1038/bjc.2017.267. Epub 2017 Aug 17.

9.

Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study.

Szender JB, Emmons T, Belliotti S, Dickson D, Khan A, Morrell K, Khan ANMN, Singel KL, Mayor PC, Moysich KB, Odunsi K, Segal BH, Eng KH.

Gynecol Oncol. 2017 Sep;146(3):491-497. doi: 10.1016/j.ygyno.2017.06.008. Epub 2017 Jun 16.

10.

The association of lifetime physical inactivity with bladder and renal cancer risk: A hospital-based case-control analysis.

Cannioto R, Etter JL, Guterman LB, Joseph JM, Gulati NR, Schmitt KL, LaMonte MJ, Nagy R, Minlikeeva A, Szender JB, Moysich KB.

Cancer Epidemiol. 2017 Aug;49:24-29. doi: 10.1016/j.canep.2017.04.017. Epub 2017 May 18.

11.

Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer.

Eng KH, Morrell K, Starbuck K, Spring-Robinson C, Khan A, Cleason D, Akman L, Zsiros E, Odunsi K, Szender JB.

Gynecol Oncol. 2017 Jul;146(1):52-57. doi: 10.1016/j.ygyno.2017.05.005. Epub 2017 May 8.

12.

NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.

Szender JB, Papanicolau-Sengos A, Eng KH, Miliotto AJ, Lugade AA, Gnjatic S, Matsuzaki J, Morrison CD, Odunsi K.

Gynecol Oncol. 2017 Jun;145(3):420-425. doi: 10.1016/j.ygyno.2017.03.509. Epub 2017 Apr 6.

13.

History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium.

Minlikeeva AN, Freudenheim JL, Cannioto RA, Szender JB, Eng KH, Modugno F, Ness RB, LaMonte MJ, Friel G, Segal BH, Odunsi K, Mayor P, Zsiros E, Schmalfeldt B, Klapdor R, Dӧrk T, Hillemanns P, Kelemen LE, Kӧbel M, Steed H, de Fazio A; Australian Ovarian Cancer Study Group, Jordan SJ, Nagle CM, Risch HA, Rossing MA, Doherty JA, Goodman MT, Edwards R, Matsuo K, Mizuno M, Karlan BY, Kjær SK, Høgdall E, Jensen A, Schildkraut JM, Terry KL, Cramer DW, Bandera EV, Paddock LE, Kiemeney LA, Massuger LF, Kupryjanczyk J, Berchuck A, Chang-Claude J, Diergaarde B, Webb PM, Moysich KB; Ovarian Cancer Association Consortium.

Cancer Causes Control. 2017 May;28(5):469-486. doi: 10.1007/s10552-017-0867-1. Epub 2017 Mar 14.

14.

Surgical Competency for Robot-Assisted Hysterectomy: Development and Validation of a Robotic Hysterectomy Assessment Score (RHAS).

Frederick PJ, Szender JB, Hussein AA, Kesterson JP, Shelton JA, Anderson TL, Barnabei VM, Guru K.

J Minim Invasive Gynecol. 2017 Jan 1;24(1):55-61. doi: 10.1016/j.jmig.2016.10.004. Epub 2016 Oct 22.

PMID:
27780777
15.

The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer: A Brief Report.

Cannioto RA, Sucheston-Campbell LE, Hampras S, Goode EL, Knutson K, Ness R, Modugno F, Wallace P, Szender JB, Mayor P, Hong CC, Joseph JM, Friel G, Davis W, Nesline M, Eng KH, Edwards RP, Kruszka B, Schmitt K, Odunsi K, Moysich KB.

Int J Gynecol Cancer. 2017 Jan;27(1):11-16. doi: 10.1097/IGC.0000000000000845.

16.

Evaluation of Metachronous Breast and Endometrial Cancers: Preroutine and Postroutine Adjuvant Tamoxifen Use.

Grzankowski KS, Szender JB, Spring-Robinson CL, Lele SB, Odunsi KO, Frederick PJ.

Int J Gynecol Cancer. 2016 Oct;26(8):1440-1447. doi: 10.1097/IGC.0000000000000785.

PMID:
30814134
17.

No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.

Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, Hu Q, Szender JB, Minlikeeva A, Joseph JM, Mayor P, Abrams SI, Segal BH, Wallace PK, Soh KT, Zsiros E, Anton-Culver H, Bandera EV, Beckmann MW, Berchuck A, Bjorge L, Bruegl A, Campbell IG, Campbell SP, Chenevix-Trench G, Cramer DW, Dansonka-Mieszkowska A, Dao F, Diergaarde B, Doerk T, Doherty JA, du Bois A, Eccles D, Engelholm SA, Fasching PA, Gayther SA, Gentry-Maharaj A, Glasspool RM, Goodman MT, Gronwald J, Harter P, Hein A, Heitz F, Hillemmanns P, Høgdall C, Høgdall EV, Huzarski T, Jensen A, Johnatty SE, Jung A, Karlan BY, Klapdor R, Kluz T, Konopka B, Kjær SK, Kupryjanczyk J, Lambrechts D, Lester J, Lubiński J, Levine DA, Lundvall L, McGuire V, McNeish IA, Menon U, Modugno F, Ness RB, Orsulic S, Paul J, Pearce CL, Pejovic T, Pharoah P, Ramus SJ, Rothstein J, Rossing MA, Rübner M, Schildkraut JM, Schmalfeldt B, Schwaab I, Siddiqui N, Sieh W, Sobiczewski P, Song H, Terry KL, Van Nieuwenhuysen E, Vanderstichele A, Vergote I, Walsh CS, Webb PM, Wentzensen N, Whittemore AS, Wu AH, Ziogas A, Odunsi K, Chang-Claude J, Goode EL, Moysich KB; Australian Ovarian Cancer Study.

Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):420-424. doi: 10.1158/1055-9965.EPI-16-0631. Epub 2016 Sep 27.

18.

Evaluation of Metachronous Breast and Endometrial Cancers: Preroutine and Postroutine Adjuvant Tamoxifen Use.

Grzankowski KS, Szender JB, Spring-Robinson CL, Lele SB, Odunsi KO, Frederick PJ.

Int J Gynecol Cancer. 2016 Oct;26(8):1440-7. doi: 10.1097/IGC.0000000000000785.

19.

Evaluation of satisfaction with work-life balance among U.S. Gynecologic Oncology fellows: A cross-sectional study.

Szender JB, Grzankowski KS, Eng KH, Odunsi K, Frederick PJ.

Gynecol Oncol Rep. 2016 Mar 9;16:17-20. doi: 10.1016/j.gore.2016.03.001. eCollection 2016 Apr.

20.

Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium.

Cannioto RA, LaMonte MJ, Kelemen LE, Risch HA, Eng KH, Minlikeeva AN, Hong CC, Szender JB, Sucheston-Campbell L, Joseph JM, Berchuck A, Chang-Claude J, Cramer DW, DeFazio A, Diergaarde B, Dörk T, Doherty JA, Edwards RP, Fridley BL, Friel G, Goode EL, Goodman MT, Hillemanns P, Hogdall E, Hosono S, Kelley JL, Kjaer SK, Klapdor R, Matsuo K, Odunsi K, Nagle CM, Olsen CM, Paddock LE, Pearce CL, Pike MC, Rossing MA, Schmalfeldt B, Segal BH, Szamreta EA, Thompson PJ, Tseng CC, Vierkant R, Schildkraut JM, Wentzensen N, Wicklund KG, Winham SJ, Wu AH, Modugno F, Ness RB, Jensen A, Webb PM, Terry K, Bandera EV, Moysich KB.

Br J Cancer. 2016 Jun 28;115(1):95-101. doi: 10.1038/bjc.2016.153. Epub 2016 Jun 14.

21.

Evaluation of Association Between Gynecologic Oncology Fellowship Length and a Career in Academic Medicine.

Kesterson JP, Szender JB, Schaefer E, Fanning J, Lele S, Frederick P.

J Cancer Educ. 2018 Feb;33(1):141-146. doi: 10.1007/s13187-016-1043-0.

22.

Impact of Physical Inactivity on Risk of Developing Cancer of the Uterine Cervix: A Case-Control Study.

Szender JB, Cannioto R, Gulati NR, Schmitt KL, Friel G, Minlikeeva A, Platek A, Gower EH, Nagy R, Khachatryan E, Mayor PC, Kasza KA, Lele SB, Odunsi K, Moysich KB.

J Low Genit Tract Dis. 2016 Jul;20(3):230-3. doi: 10.1097/LGT.0000000000000210.

23.

HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer.

Szender JB, Eng KH, Matsuzaki J, Miliotto A, Gnjatic S, Tsuji T, Odunsi K.

Gynecol Oncol. 2016 Jul;142(1):158-162. doi: 10.1016/j.ygyno.2016.04.017. Epub 2016 Apr 23.

24.

Metabolomics of biomarker discovery in ovarian cancer: a systematic review of the current literature.

Turkoglu O, Zeb A, Graham S, Szyperski T, Szender JB, Odunsi K, Bahado-Singh R.

Metabolomics. 2016 Apr;12(4). pii: 60. doi: 10.1007/s11306-016-0990-0. Epub 2016 Mar 8.

25.

Fallopian Tube Ligation or Salpingectomy as Means for Reducing Risk of Ovarian Cancer.

Szender JB, Lele SB.

AMA J Ethics. 2015 Sep 1;17(9):843-8. doi: 10.1001/journalofethics.2015.17.9.stas1-1509. No abstract available.

26.

Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.

Eng KH, Hanlon BM, Bradley WH, Szender JB.

Gynecol Oncol. 2015 Nov;139(2):228-35. doi: 10.1016/j.ygyno.2015.09.011. Epub 2015 Sep 14.

27.

Oral Contraceptive Use and Reproductive Characteristics Affect Survival in Patients With Epithelial Ovarian Cancer: A Cohort Study.

Kolomeyevskaya NV, Szender JB, Zirpoli G, Minlikeeva A, Friel G, Cannioto RA, Brightwell RM, Grzankowski KS, Moysich KB.

Int J Gynecol Cancer. 2015 Nov;25(9):1587-92. doi: 10.1097/IGC.0000000000000540.

28.

Use of common analgesics is not associated with ovarian cancer survival.

Minlikeeva AN, Freudenheim JL, Lo-Ciganic WH, Eng KH, Friel G, Diergaarde B, Modugno F, Cannioto R, Gower E, Szender JB, Grzankowski K, Odunsi K, Ness RB, Moysich KB.

Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1291-4. doi: 10.1158/1055-9965.EPI-15-0508. Epub 2015 Jun 10.

29.

Evaluation of the National Surgical Quality Improvement Program Universal Surgical Risk Calculator for a gynecologic oncology service.

Szender JB, Frederick PJ, Eng KH, Akers SN, Lele SB, Odunsi K.

Int J Gynecol Cancer. 2015 Mar;25(3):512-20. doi: 10.1097/IGC.0000000000000378.

30.

Satisfaction with work-life balance among U.S. gynecologic oncologists, a cross-sectional study.

Szender JB, Grzankowski KS, Eng KH, Lele SB, Odunsi K, Frederick PJ.

Am J Clin Exp Obstet Gynecol. 2015;2(4):166-175.

31.

A randomized-clinical trial examining a neoprene abdominal binder in gynecologic surgery patients.

Szender JB, Hall KL, Kost ER.

Clin Exp Obstet Gynecol. 2014;41(5):525-9.

Supplemental Content

Loading ...
Support Center